Loading…

Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression

Cisplatin resistance is a main clinical problem of lung cancer therapy. Gambogic acid (GA) could prohibit the proliferation of a variety of human cancer cells. However, the effects of GA on cisplatin-resistant lung cancer are still unclear. The objective of the present study was to find out the anti...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2016-01, Vol.9, p.3359-3368
Main Authors: Zhang, Wendian, Zhou, Hechao, Yu, Ying, Li, Jingjing, Li, Haiwen, Jiang, Danxian, Chen, Zihong, Yang, Donghong, Xu, Zumin, Yu, Zhonghua
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c605t-228b91c5a28fdcbdd313607ec7d45c88c740b4a16cbabb16e7b4353231bce2413
cites
container_end_page 3368
container_issue
container_start_page 3359
container_title OncoTargets and therapy
container_volume 9
creator Zhang, Wendian
Zhou, Hechao
Yu, Ying
Li, Jingjing
Li, Haiwen
Jiang, Danxian
Chen, Zihong
Yang, Donghong
Xu, Zumin
Yu, Zhonghua
description Cisplatin resistance is a main clinical problem of lung cancer therapy. Gambogic acid (GA) could prohibit the proliferation of a variety of human cancer cells. However, the effects of GA on cisplatin-resistant lung cancer are still unclear. The objective of the present study was to find out the antitumor effects of GA on cisplatin-resistant human lung cancer A549/DDP cells and further explore its underlying mechanisms. Cell Counting Kit-8 assay was used to observe the impacts of GA and/or cisplatin on the proliferation of lung cancer cells; flow cytometry was used to detect the effects of GA on cell cycle and apoptosis; Western blot was used to examine the effects of GA on the expression of lung resistance protein (LRP) and multidrug resistance-associated protein 2 (MRP2) protein in A549/DDP cells. Our results showed that GA dose- and time-dependently prohibited the proliferation and induced significant cell apoptosis in A549 and A549/DDP cells. GA also induced G0/G1 arrest in both A549/DDP and A549 cells. Moreover, GA upregulated protein expression level of cleaved caspase-3 and Bax and downregulated protein expression level of pro-caspase-9 and Bcl-2 in time- and dose-dependent way in A549/DDP cells. GA combined with cisplatin enhanced the cells apoptotic rate and reduced the cisplatin resistance index in A549/DDP cells. In addition, GA reduced the MRP2 and LRP protein expression level in A549/DDP cells. GA inhibits the proliferation, induces cell cycle arrest and apoptosis in A549/DDP cells. Combination of GA with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.
doi_str_mv 10.2147/OTT.S100936
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4898431</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A503297065</galeid><sourcerecordid>A503297065</sourcerecordid><originalsourceid>FETCH-LOGICAL-c605t-228b91c5a28fdcbdd313607ec7d45c88c740b4a16cbabb16e7b4353231bce2413</originalsourceid><addsrcrecordid>eNqNkltrFDEYhgdRbK1eeS8BQQqya05zuhHKUg-w0lLX65BkvplJmUm2k4y1P8b_asauexChkouE5PmeLyFvkrwkeE4Jz99drFbzrwTjkmWPkmNC8mKWlQw_3lsfJc-8v8Y4ywrKnyZHNGcMM5IdJz8XrlfGymCcRa5GjeyVa4xGUpsK3ZrQIm38uouARWBbaTV4FFpA0gYTxt4NCOoadPAoGrbsbABvfIgQ6kbbID0VDkhD13mk7lDlbu0AzfgbbtCXq0sajRVaXl0i-LGO1T7e6HnypJadhxeb-ST59uF8tfg0W158_Lw4W850htMwo7RQJdGppEVdaVVVjLAM56Dziqe6KHTOseKSZFpJpUgGueIsZZQRpYFywk6S9_fe9ah6qDTYMMhOrAfTy-FOOGnE4Yk1rWjcd8GLsuBsEpxuBIO7GcEH0Rs_PVZacKMXJC9LSighNKKv_0Kv3TjY-DxBKccc0xKTHdXIDoSxtYt99SQVZylmtMxxlj5AYVpMTSM1_wcVRwW90c5CbeL-gfY_C3Yd3uwVtCC70HrXjVOq_KH5AXBnfHsP6sF5P0C9_QyCxRR7EWMvNrGP9Kv9_9uyf3LOfgGd4vv8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2240402901</pqid></control><display><type>article</type><title>Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression</title><source>PubMed (Medline)</source><source>Taylor &amp; Francis Open Access</source><source>Publicly Available Content Database</source><creator>Zhang, Wendian ; Zhou, Hechao ; Yu, Ying ; Li, Jingjing ; Li, Haiwen ; Jiang, Danxian ; Chen, Zihong ; Yang, Donghong ; Xu, Zumin ; Yu, Zhonghua</creator><creatorcontrib>Zhang, Wendian ; Zhou, Hechao ; Yu, Ying ; Li, Jingjing ; Li, Haiwen ; Jiang, Danxian ; Chen, Zihong ; Yang, Donghong ; Xu, Zumin ; Yu, Zhonghua</creatorcontrib><description>Cisplatin resistance is a main clinical problem of lung cancer therapy. Gambogic acid (GA) could prohibit the proliferation of a variety of human cancer cells. However, the effects of GA on cisplatin-resistant lung cancer are still unclear. The objective of the present study was to find out the antitumor effects of GA on cisplatin-resistant human lung cancer A549/DDP cells and further explore its underlying mechanisms. Cell Counting Kit-8 assay was used to observe the impacts of GA and/or cisplatin on the proliferation of lung cancer cells; flow cytometry was used to detect the effects of GA on cell cycle and apoptosis; Western blot was used to examine the effects of GA on the expression of lung resistance protein (LRP) and multidrug resistance-associated protein 2 (MRP2) protein in A549/DDP cells. Our results showed that GA dose- and time-dependently prohibited the proliferation and induced significant cell apoptosis in A549 and A549/DDP cells. GA also induced G0/G1 arrest in both A549/DDP and A549 cells. Moreover, GA upregulated protein expression level of cleaved caspase-3 and Bax and downregulated protein expression level of pro-caspase-9 and Bcl-2 in time- and dose-dependent way in A549/DDP cells. GA combined with cisplatin enhanced the cells apoptotic rate and reduced the cisplatin resistance index in A549/DDP cells. In addition, GA reduced the MRP2 and LRP protein expression level in A549/DDP cells. GA inhibits the proliferation, induces cell cycle arrest and apoptosis in A549/DDP cells. Combination of GA with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S100936</identifier><identifier>PMID: 27330316</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Apoptosis ; Breast cancer ; Cancer therapies ; Carboxylic acids ; Care and treatment ; Cell cycle ; Cell growth ; Chemotherapy ; Cisplatin ; Colorectal cancer ; Dosage and administration ; Drug resistance ; Drug synergism ; Drug therapy ; Esophagus ; Flow cytometry ; Health aspects ; Lung cancer ; Medical research ; Multidrug resistant organisms ; Original Research ; Patient outcomes ; Proteins ; Testing</subject><ispartof>OncoTargets and therapy, 2016-01, Vol.9, p.3359-3368</ispartof><rights>COPYRIGHT 2016 Dove Medical Press Limited</rights><rights>2016. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2016 Zhang et al. This work is published and licensed by Dove Medical Press Limited 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c605t-228b91c5a28fdcbdd313607ec7d45c88c740b4a16cbabb16e7b4353231bce2413</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2240402901/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2240402901?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27330316$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Wendian</creatorcontrib><creatorcontrib>Zhou, Hechao</creatorcontrib><creatorcontrib>Yu, Ying</creatorcontrib><creatorcontrib>Li, Jingjing</creatorcontrib><creatorcontrib>Li, Haiwen</creatorcontrib><creatorcontrib>Jiang, Danxian</creatorcontrib><creatorcontrib>Chen, Zihong</creatorcontrib><creatorcontrib>Yang, Donghong</creatorcontrib><creatorcontrib>Xu, Zumin</creatorcontrib><creatorcontrib>Yu, Zhonghua</creatorcontrib><title>Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>Cisplatin resistance is a main clinical problem of lung cancer therapy. Gambogic acid (GA) could prohibit the proliferation of a variety of human cancer cells. However, the effects of GA on cisplatin-resistant lung cancer are still unclear. The objective of the present study was to find out the antitumor effects of GA on cisplatin-resistant human lung cancer A549/DDP cells and further explore its underlying mechanisms. Cell Counting Kit-8 assay was used to observe the impacts of GA and/or cisplatin on the proliferation of lung cancer cells; flow cytometry was used to detect the effects of GA on cell cycle and apoptosis; Western blot was used to examine the effects of GA on the expression of lung resistance protein (LRP) and multidrug resistance-associated protein 2 (MRP2) protein in A549/DDP cells. Our results showed that GA dose- and time-dependently prohibited the proliferation and induced significant cell apoptosis in A549 and A549/DDP cells. GA also induced G0/G1 arrest in both A549/DDP and A549 cells. Moreover, GA upregulated protein expression level of cleaved caspase-3 and Bax and downregulated protein expression level of pro-caspase-9 and Bcl-2 in time- and dose-dependent way in A549/DDP cells. GA combined with cisplatin enhanced the cells apoptotic rate and reduced the cisplatin resistance index in A549/DDP cells. In addition, GA reduced the MRP2 and LRP protein expression level in A549/DDP cells. GA inhibits the proliferation, induces cell cycle arrest and apoptosis in A549/DDP cells. Combination of GA with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.</description><subject>Apoptosis</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Carboxylic acids</subject><subject>Care and treatment</subject><subject>Cell cycle</subject><subject>Cell growth</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Colorectal cancer</subject><subject>Dosage and administration</subject><subject>Drug resistance</subject><subject>Drug synergism</subject><subject>Drug therapy</subject><subject>Esophagus</subject><subject>Flow cytometry</subject><subject>Health aspects</subject><subject>Lung cancer</subject><subject>Medical research</subject><subject>Multidrug resistant organisms</subject><subject>Original Research</subject><subject>Patient outcomes</subject><subject>Proteins</subject><subject>Testing</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqNkltrFDEYhgdRbK1eeS8BQQqya05zuhHKUg-w0lLX65BkvplJmUm2k4y1P8b_asauexChkouE5PmeLyFvkrwkeE4Jz99drFbzrwTjkmWPkmNC8mKWlQw_3lsfJc-8v8Y4ywrKnyZHNGcMM5IdJz8XrlfGymCcRa5GjeyVa4xGUpsK3ZrQIm38uouARWBbaTV4FFpA0gYTxt4NCOoadPAoGrbsbABvfIgQ6kbbID0VDkhD13mk7lDlbu0AzfgbbtCXq0sajRVaXl0i-LGO1T7e6HnypJadhxeb-ST59uF8tfg0W158_Lw4W850htMwo7RQJdGppEVdaVVVjLAM56Dziqe6KHTOseKSZFpJpUgGueIsZZQRpYFywk6S9_fe9ah6qDTYMMhOrAfTy-FOOGnE4Yk1rWjcd8GLsuBsEpxuBIO7GcEH0Rs_PVZacKMXJC9LSighNKKv_0Kv3TjY-DxBKccc0xKTHdXIDoSxtYt99SQVZylmtMxxlj5AYVpMTSM1_wcVRwW90c5CbeL-gfY_C3Yd3uwVtCC70HrXjVOq_KH5AXBnfHsP6sF5P0C9_QyCxRR7EWMvNrGP9Kv9_9uyf3LOfgGd4vv8</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Zhang, Wendian</creator><creator>Zhou, Hechao</creator><creator>Yu, Ying</creator><creator>Li, Jingjing</creator><creator>Li, Haiwen</creator><creator>Jiang, Danxian</creator><creator>Chen, Zihong</creator><creator>Yang, Donghong</creator><creator>Xu, Zumin</creator><creator>Yu, Zhonghua</creator><general>Dove Medical Press Limited</general><general>Taylor &amp; Francis Ltd</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160101</creationdate><title>Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression</title><author>Zhang, Wendian ; Zhou, Hechao ; Yu, Ying ; Li, Jingjing ; Li, Haiwen ; Jiang, Danxian ; Chen, Zihong ; Yang, Donghong ; Xu, Zumin ; Yu, Zhonghua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c605t-228b91c5a28fdcbdd313607ec7d45c88c740b4a16cbabb16e7b4353231bce2413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Apoptosis</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Carboxylic acids</topic><topic>Care and treatment</topic><topic>Cell cycle</topic><topic>Cell growth</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Colorectal cancer</topic><topic>Dosage and administration</topic><topic>Drug resistance</topic><topic>Drug synergism</topic><topic>Drug therapy</topic><topic>Esophagus</topic><topic>Flow cytometry</topic><topic>Health aspects</topic><topic>Lung cancer</topic><topic>Medical research</topic><topic>Multidrug resistant organisms</topic><topic>Original Research</topic><topic>Patient outcomes</topic><topic>Proteins</topic><topic>Testing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Wendian</creatorcontrib><creatorcontrib>Zhou, Hechao</creatorcontrib><creatorcontrib>Yu, Ying</creatorcontrib><creatorcontrib>Li, Jingjing</creatorcontrib><creatorcontrib>Li, Haiwen</creatorcontrib><creatorcontrib>Jiang, Danxian</creatorcontrib><creatorcontrib>Chen, Zihong</creatorcontrib><creatorcontrib>Yang, Donghong</creatorcontrib><creatorcontrib>Xu, Zumin</creatorcontrib><creatorcontrib>Yu, Zhonghua</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest research library</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Wendian</au><au>Zhou, Hechao</au><au>Yu, Ying</au><au>Li, Jingjing</au><au>Li, Haiwen</au><au>Jiang, Danxian</au><au>Chen, Zihong</au><au>Yang, Donghong</au><au>Xu, Zumin</au><au>Yu, Zhonghua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>9</volume><spage>3359</spage><epage>3368</epage><pages>3359-3368</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>Cisplatin resistance is a main clinical problem of lung cancer therapy. Gambogic acid (GA) could prohibit the proliferation of a variety of human cancer cells. However, the effects of GA on cisplatin-resistant lung cancer are still unclear. The objective of the present study was to find out the antitumor effects of GA on cisplatin-resistant human lung cancer A549/DDP cells and further explore its underlying mechanisms. Cell Counting Kit-8 assay was used to observe the impacts of GA and/or cisplatin on the proliferation of lung cancer cells; flow cytometry was used to detect the effects of GA on cell cycle and apoptosis; Western blot was used to examine the effects of GA on the expression of lung resistance protein (LRP) and multidrug resistance-associated protein 2 (MRP2) protein in A549/DDP cells. Our results showed that GA dose- and time-dependently prohibited the proliferation and induced significant cell apoptosis in A549 and A549/DDP cells. GA also induced G0/G1 arrest in both A549/DDP and A549 cells. Moreover, GA upregulated protein expression level of cleaved caspase-3 and Bax and downregulated protein expression level of pro-caspase-9 and Bcl-2 in time- and dose-dependent way in A549/DDP cells. GA combined with cisplatin enhanced the cells apoptotic rate and reduced the cisplatin resistance index in A549/DDP cells. In addition, GA reduced the MRP2 and LRP protein expression level in A549/DDP cells. GA inhibits the proliferation, induces cell cycle arrest and apoptosis in A549/DDP cells. Combination of GA with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>27330316</pmid><doi>10.2147/OTT.S100936</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1178-6930
ispartof OncoTargets and therapy, 2016-01, Vol.9, p.3359-3368
issn 1178-6930
1178-6930
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4898431
source PubMed (Medline); Taylor & Francis Open Access; Publicly Available Content Database
subjects Apoptosis
Breast cancer
Cancer therapies
Carboxylic acids
Care and treatment
Cell cycle
Cell growth
Chemotherapy
Cisplatin
Colorectal cancer
Dosage and administration
Drug resistance
Drug synergism
Drug therapy
Esophagus
Flow cytometry
Health aspects
Lung cancer
Medical research
Multidrug resistant organisms
Original Research
Patient outcomes
Proteins
Testing
title Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-31T23%3A52%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20of%20gambogic%20acid%20with%20cisplatin%20enhances%20the%20antitumor%20effects%20on%20cisplatin-resistant%20lung%20cancer%20cells%20by%20downregulating%20MRP2%20and%20LRP%20expression&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Zhang,%20Wendian&rft.date=2016-01-01&rft.volume=9&rft.spage=3359&rft.epage=3368&rft.pages=3359-3368&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S100936&rft_dat=%3Cgale_pubme%3EA503297065%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c605t-228b91c5a28fdcbdd313607ec7d45c88c740b4a16cbabb16e7b4353231bce2413%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2240402901&rft_id=info:pmid/27330316&rft_galeid=A503297065&rfr_iscdi=true